Axsome Q2 2026 revenue up 46% to $218.4M; AUVELITY Alzheimer's launch underway

Axsome Therapeutics, Inc.

Total net product revenue $218.4M, +46% YoY; AUVELITY sales $180.3M (+51% YoY), SUNOSI $35.8M (+20%), SYMBRAVO $2.3M (+461%).
Net loss $51.3M ($0.99/share) vs $48.0M loss ($0.97) in Q2 2025; SG&A up to $208.1M from $130.3M on launch activities.
AUVELITY launched for Alzheimer's disease agitation in June 2026; new-to-brand Rx +126% in patients ≥65 in first 8 weeks.
NDA for AXS-12 (cataplexy in narcolepsy) accepted by FDA; PDUFA target action date May 1, 2027.
Cash $319.9M at June 30, 2026; guidance says sufficient to fund operations into cash flow positivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.